Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
Poster: SySAdmin
Posted on December 3, 2010 at 1:00:01 PM
Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
MuGard Website Features Video And Additional Written Clinician Feedback
DALLAS and NEW YORK, Dec. 3, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP),a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,announced it has updated its lead product website, http://www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.
The video can be found under the Testimonial section of the MuGard website (http://www.MuGard.com), or by clicking on the following link: http://www.MuGard.com/testimonials/.
"We continue receiving many anecdotal feedback and testimonials from patients, doctors, and nurses," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals. He continued, "We are gratified at the overwhelmingly positive reception MuGard is receiving in the oncology community and we plan to continue updating the site with additional testimonials that demonstrate the significant clinical benefit experienced using MuGard in both a prophylactic and treatment setting."
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard(TM) (http://www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac(TM), a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine(TM), a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte(TM)-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations
---------------- ---------------------------
Donald C. Weinberger/Diana Bittner
Christine Berni (media)
Director of Investor
Relations Wolfe Axelrod Weinberger Assoc. LLC
Access Pharmaceuticals, Inc. (212) 370-4500
(212) 786-6208
SOURCE Access Pharmaceuticals, Inc.
Access Pharmaceuticals, Inc.
CONTACT: Christine Berni, Director of Investor Relations of Access Pharmaceuticals, Inc., +1-212-786-6208, or Investor Relations, Donald C. Weinberger or Diana Bittner, +1-212-370-4500, both of Wolfe Axelrod Weinberger Assoc. LLC, for Access Pharmaceuticals, Inc.
Web Site: http://www.accesspharma.com
MuGard Website Features Video And Additional Written Clinician Feedback
DALLAS and NEW YORK, Dec. 3, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP),a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,announced it has updated its lead product website, http://www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.
The video can be found under the Testimonial section of the MuGard website (http://www.MuGard.com), or by clicking on the following link: http://www.MuGard.com/testimonials/.
"We continue receiving many anecdotal feedback and testimonials from patients, doctors, and nurses," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals. He continued, "We are gratified at the overwhelmingly positive reception MuGard is receiving in the oncology community and we plan to continue updating the site with additional testimonials that demonstrate the significant clinical benefit experienced using MuGard in both a prophylactic and treatment setting."
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard(TM) (http://www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac(TM), a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine(TM), a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte(TM)-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations
---------------- ---------------------------
Donald C. Weinberger/Diana Bittner
Christine Berni (media)
Director of Investor
Relations Wolfe Axelrod Weinberger Assoc. LLC
Access Pharmaceuticals, Inc. (212) 370-4500
(212) 786-6208
SOURCE Access Pharmaceuticals, Inc.
Access Pharmaceuticals, Inc.
CONTACT: Christine Berni, Director of Investor Relations of Access Pharmaceuticals, Inc., +1-212-786-6208, or Investor Relations, Donald C. Weinberger or Diana Bittner, +1-212-370-4500, both of Wolfe Axelrod Weinberger Assoc. LLC, for Access Pharmaceuticals, Inc.
Web Site: http://www.accesspharma.com